DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx. Recall

Ongoing
Drugs
Class II — Moderate

Recall Date

Jul 1, 2026

Company

Direct Rx

Source

FDA

Units

263 Bottles

Reason: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Class II: Use of the product may cause temporary or medically reversible health problems.

Official FDA recall notice

Information is from official FDA notices. Do not stop taking any medication without consulting your doctor or pharmacist first — the risks of stopping may be greater than the risk from the recalled product.

Recall Details

Description

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Product: DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.
Official Recall ID: FDA-DRUG-D-0617-2026
Units affected: 263 Bottles

What Should I Do?

Check your lot number. Don't stop taking a prescribed medication without talking to your pharmacist or doctor. Contact the pharmacy where you got it about a replacement.

Quantity: 263 Bottles

Remediation GuideAction Required

5-step guide to help you action required this recalled product. Click Start Remediation to track your progress.

1
Confirm Your Product Is Affected
2
Read the Full Recall Notice
3
Stop Using the Product if in Doubt

+2 more steps…

View Official Recall Notice (FDA)

Last updated July 6, 2026

Injured by a recalled product?

Our legal partners offer free consultations for recall victims.

Get Free Legal Help →Sponsored

Stay Informed

Weekly recall digest — free, no spam.